Medicine and Dentistry
Neoplasm
100%
Pediatrics
85%
Ganglioglioma
74%
Intracranial Tumor
55%
Malignant Neoplasm
47%
DNA Mismatch Repair
45%
Medulloblastoma
30%
Pediatrics Patient
29%
Neurofibromatosis Type I
29%
Visual Acuity
26%
Retinoblastoma
26%
Overall Survival
22%
Methotrexate
21%
Drug Megadose
18%
Magnetic Resonance Imaging
17%
Infection
17%
Metastatic Carcinoma
17%
Craniospinal Irradiation
16%
MEK Inhibitor
15%
Optical Coherence Tomography
14%
Diseases
14%
Atypical Teratoid Rhabdoid Tumor
14%
Cancer Surgery
13%
microRNA
13%
Ependymoma
13%
Visual Field
13%
Cohort Analysis
13%
Ewing Sarcoma
13%
Cerebrospinal Fluid
13%
COVID-19
13%
Plexiform Neurofibroma
13%
Medicine
13%
Optic Neuropathy
12%
Optic Nerve
12%
Cancer Susceptibility
12%
Prevalence
11%
Gene Repair
11%
Cancer
11%
Adverse Event
11%
Event Free Survival
10%
Visual Impairment
10%
Hydrocephalus
10%
Pediatric Brain Tumor
9%
Rosette Formation
9%
Trametinib
9%
Pediatric Cancer
9%
Limb
9%
Germ Cell
9%
Deterioration
8%
Gene Mutation
8%
Keyphrases
Tumor
57%
Neurofibromatosis Type 1 (NF-1)
45%
Constitutional Mismatch Repair Deficiency (CMMRD)
39%
Medulloblastoma
36%
Optic Pathway Glioma
36%
Brain Tumor
34%
Pediatric Patients
31%
Chemotherapy
30%
Pediatric
30%
Pediatric Low-grade Glioma
29%
Young children
26%
Neurofibromatosis Type I
26%
Retinoblastoma
26%
Visual Acuity
25%
Methotrexate
21%
BRAF Inhibitor (BRAFi)
20%
Relapsed or Refractory
19%
Ewing Sarcoma
19%
Event-free Survival
19%
Working Diagnosis
18%
Molecular Subgroups
16%
MEK Inhibitor (MEKi)
16%
High Dose
15%
Craniospinal Irradiation
15%
Mismatch Repair Genes
15%
Ophthalmological
15%
Treatment Protocol
14%
Risk Factors
14%
COVID-19
14%
Atypical Teratoid Rhabdoid Tumor (AT/RT)
14%
Optical Coherence Tomography
14%
PMS2
14%
Overall Survival
14%
Medulloblastoma Subgroups
14%
Plexiform Neurofibroma
13%
Firefly
13%
Pilot Treatment
13%
Cerebrospinal Fluid
13%
Mismatch Repair
13%
Registry Study
13%
Genome Analysis
13%
Rare Brain Tumours
13%
Pediatric Population
12%
Optic Neuropathy
12%
Failed Repair
12%
Medical Center
11%
Clinical Data
11%
Visual Loss
11%
Founder mutation
10%
Trametinib
10%